On July 1, 2022 Pharmaxis Limited (ASX:PSX), a clinical stage drug development company developing novel therapies to treat inflammatory and fibrotic diseases, reported the appointment of Dr Jana Baskar to the role of Chief Medical Officer (Press release, Pharmaxis, JUL 1, 2022, View Source;utm_campaign=Appointment%20of%20Jana%20Basker&utm_content=Appointment%20of%20Jana%20Basker+CID_bca45eeb80226d41b6b06560a3261988&utm_source=Campaign%20Monitor&utm_term=View%20Full%20Media%20Release [SID1234616441]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr Baskar is a highly experienced executive who has worked in both pharmaceutical and contract research companies.
"We are delighted to welcome Dr Baskar to Pharmaxis, where his deep experience leading clinical programs will be an asset to the continued advancement of our pipeline," commented Gary Phillips, Chief Executive Officer of Pharmaxis. "Dr Baskar brings significant oversight, clinical development and strategic expertise, having previously guided numerous programs through all phases of development. His extensive background and experience will be particularly valuable as the Company progresses its lead asset, PXS‐5505, towards clinical proof of concept in myelofibrosis and other oncology indications."
Dr Jana Baskar has over two decades of experience including overseeing more than 70 phase I‐III trials of oncology treatments in his 6 years as Medical Director at Novartis Oncology in Australia. In his most recent role, he served as Medical Director for IQVIA in Australia and New Zealand where he also co‐ chaired the IQVIA ANZ Oncology Advisory Board providing strategic advice to Biopharma companies. Dr Baskar received his Bachelor of Medicine degree (MBBS) from the University of Western Australia. He holds a Master of Medical Science in Drug Development from the University of New South Wales, Sydney (MMedSc) and a Masters of Business Administration (MBA) from the Australian Graduate School of Management.
Pharmaxis founding scientist and Medical Director, Dr Brett Charlton, is retiring after more than 20 years’ service with the company during which time he has overseen development programs that lead to two products achieving global regulatory approval and the transition of several pipeline products into clinical development including Pharmaxis’ two lead assets in myelofibrosis (PXS‐5505) and scarring (PXS‐6302). Page 2 of 3 Gary Phillips said, "I’d like to recognise and sincerely thank Dr Charlton for his extensive contribution to the Pharmaxis business and to advances in patient care. His experience and knowledge of transitioning drugs into early phase development has been extremely valuable and we will continue to seek his advice in a part time consultancy capacity until the end of 2022."